BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

Stefan Oschmann will hand the titles of executive board chair and CEO of Merck KGaA (Xetra:MRK) to Belén Garijo on May 1, 2021. Garijo is the German company’s vice chair and deputy CEO, as well...
BioCentury | Sep 29, 2020
Finance

With $77M series B, condensates company Dewpoint aiming for proof of concept

Dewpoint’s $77 million series B round affords the company “breathing room to make good decisions” as it chooses programs to develop and partner based on the science of biomolecular condensates, CEO Amir Nashat told BioCentury....
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...Generic), Opdivo (Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Amgen Inc. Bristol-Myers...
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

Priority Review for bluebird-BMS program could fulfill CVR goalFDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc. (NASDAQ:BLUE) and Bristol Myers Squibb Co. (NYSE:BMY) suggests that an approval decision could come before...
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

With its €380 million takeout of Dublin-based Inflazome, Roche is continuing the rush of pharmas targeting inflammasome companies in a deal that leaves NodThera as the last company standing among the first crop of high...
BioCentury | Sep 22, 2020
Deals

Grail chooses Illumina takeout over IPO, promising more future returns for shareholders

Rather than going public as planned, early cancer detection company Grail chose to be acquired by Illumina in a deal that will provide immediate returns to the outside investors that backed its spinout...
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

Over the past few years Novo Ventures has been ramping up the pace and size of its biotech investments, with Thursday’s $83 million series C round by γδ T cell engager company Lava the latest...
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

Synthekine is translating the structural biology work of Stanford synthetic cytokine pioneer K. Chris Garcia into a broad platform that could generate therapeutic cytokine signals never seen in nature.   The company, which launched Thursday with...
BioCentury | Sep 11, 2020
Product Development

ACTIV-4 trials to zero in on best agents and disease stages for addressing blood clots in COVID-19

NIH’s trio of adaptive ACTIV-4 Antithrombotics studies are going beyond identifying which drugs most effectively prevent blood clots in individuals infected with SARS-CoV-2 to figuring out when in the...
Items per page:
1 - 10 of 6872